Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.87 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
1.82 |
0.99 |
-0.83 |
-45.60% |
2024-05-10 |
2024-03 |
-1.04 |
-1.05 |
-0.01 |
-0.96% |
2024-02-28 |
2023-12 |
-0.49 |
-1.44 |
-0.95 |
-193.88% |
2023-11-09 |
2023-09 |
-1.82 |
-1.26 |
0.56 |
30.77% |
2023-08-08 |
2023-06 |
-1.24 |
0.58 |
1.82 |
146.77% |
Date |
Firm |
Action |
From |
To |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-08 |
B. Riley Securities |
Upgrade |
Neutral |
Buy |
2023-05-09 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-02-28 |
B. Riley Securities |
Downgrade |
Buy |
Neutral |
2023-02-12 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-01-01 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-06-11 |
ALTON GREGG H |
Director |
10.47K |
Conversion of Exercise of derivative security |
2024-06-11 |
DOUGLAS RICHARD H |
Director |
43.92K |
Conversion of Exercise of derivative security |
2024-06-16 |
DUBOVSKY FILIP |
Officer |
66.61K |
Conversion of Exercise of derivative security |
2024-08-15 |
KELLY JAMES PATRICK |
Chief Financial Officer |
14.43K |
Conversion of Exercise of derivative security |
2024-06-11 |
KING RACHEL K |
Director |
18.92K |
Conversion of Exercise of derivative security |
2024-06-11 |
MCGLYNN MARGARET G |
Director |
10.47K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
State Street Corporation |
11.68M |
86.78M |
12.37% |
2023-06-29 |
Vanguard Group Inc |
10.57M |
78.55M |
11.20% |
2023-06-29 |
Blackrock Inc. |
6.99M |
51.97M |
7.41% |
2023-09-29 |
Shah Capital Management |
6.33M |
45.83M |
6.71% |
2023-06-29 |
Bank of America Corporation |
2.18M |
16.23M |
2.31% |
2023-06-29 |
Morgan Stanley |
2.08M |
15.46M |
2.20% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
9.38M |
75.07M |
9.94% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.64M |
19.60M |
2.79% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.23M |
16.56M |
2.36% |
2023-08-30 |
iShares Russell 2000 ETF |
2.01M |
16.10M |
2.13% |
2023-06-29 |
Vanguard Small-Cap Growth Index Fund |
1.28M |
9.48M |
1.35% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.21M |
8.98M |
1.28% |
Split |
Date |
1 : 20 |
2019-05-10 |